Progress in the mechanism and drug development of castration-resistant prostate cancer.

about

RNF7 knockdown inhibits prostate cancer tumorigenesis by inactivation of ERK1/2 pathway.Anti-Prostate Cancer Activity of 8-Hydroxyquinoline-2-Carboxaldehyde-Thiosemicarbazide Copper Complexes by Fluorescent Microscopic Imaging.

P2860

Q37676275-DE2C63BC-F6F6-4AD5-AF96-F748DAF5F6A1 Q48219468-E4863ED9-91D1-42C3-B98A-6B571D23070B

P2860

Progress in the mechanism and drug development of castration-resistant prostate cancer.

Item

http://www.wikidata.org/entity/Q38826609

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Progress in the mechanism and drug development of castration-resistant prostate cancer.

@en

type

Item

label

Progress in the mechanism and drug development of castration-resistant prostate cancer.

@en

prefLabel

Progress in the mechanism and drug development of castration-resistant prostate cancer.

@en

P1476

Progress in the mechanism and drug development of castration-resistant prostate cancer.

@en

P2093

Minzan Zuo

http://www.w3.org/2001/XMLSchema#string

Raoling Ge

http://www.w3.org/2001/XMLSchema#string

Tinghan Li

http://www.w3.org/2001/XMLSchema#string

Xi Xu

http://www.w3.org/2001/XMLSchema#string

Zhiyu Li

http://www.w3.org/2001/XMLSchema#string

P2860

LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion

Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC)

Tubulin-interactive natural products as anticancer agents

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

Structure and specificity of nuclear receptor-coactivator interactions

P304

765-788

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.4155/FMC.16.12

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27149562

http://www.w3.org/2001/XMLSchema#string

Progress in the mechanism and drug development of castration-resistant prostate cancer.

about

P2860

P2860

Progress in the mechanism and drug development of castration-resistant prostate cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698